Impact of a pharmacist-led hepatitis C clinic on hepatitis A and B vaccination rates and treatment outcomes: A retrospective cohort study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
BACKGROUND: Hepatitis C virus (HCV) affects approximately 2.4 million people in the United States, with Kentucky having one of the highest HCV infection rates. The Centers for Disease Control and Prevention (CDC) recommend that all patients diagnosed with HCV be screened and vaccinated as appropriate for hepatitis A virus (HAV) and hepatitis B virus (HBV). Despite these long-standing recommendations, vaccination rates remain below target goals. OBJECTIVE: To evaluate the impact of a pharmacist-led Medication Management Clinic (MMC) on HAV and HBV vaccination rates and other treatment outcomes in patients diagnosed with HCV compared with a traditional care model. METHODS: This retrospective cohort study compared patients diagnosed with HCV treated through a pharmacist-led MMC between August 1, 2022, and February 28, 2024, with those treated through traditional care between August 1, 2016, and February 28, 2018. Primary outcomes included HAV and HBV vaccination initiation rates among eligible patients. Secondary outcomes included screening rates for HAV and HBV, HCV treatment completion, sustained virologic response (SVR), and specialty pharmacy prescription retention. Logistic regression was performed to assess the relationship between vaccination rates and type of care received (traditional care vs MMC), adjusting for baseline demographic and clinical factors, including, age, sex, HCV genotype, and fibrosis stage. Adjusted odds ratios (aORs) with 95% CIs were calculated for HAV and HBV initiation. RESULTS: = 0.06). The specialty pharmacy prescription retention rate in the MMC group was 81.0%. CONCLUSIONS: In a setting where HAV and HBV vaccination guidelines remained consistent over time, the pharmacist-led MMC model was associated with higher vaccination and screening rates compared with the traditional care model, and these associations remained robust after adjustment for age, sex, genotype, and fibrosis stage. The model may have contributed to increased treatment initiation during a period of evolving HCV treatment guidelines. These findings support the potential value of pharmacist-led collaborative care agreements in delivering comprehensive HCV management during a period of evolving HCV treatment guidelines. These findings support the potential value of pharmacist-led collaborative care agreements in delivering comprehensive HCV management.
Fields of Study & Subjects
Hepatitis C virus research
Pharmacy and Medical Practices
Vaccine Coverage and Hesitancy
Publication details
- Journal / source
- Journal of Managed Care & Specialty Pharmacy
- Volume
- 32
- Issue
- 4
- Pages
- 485–493
- Publication date
- 26 March 2026
- Language
- EN